Bone Marrow Mesenchymal Stem Cells: Biological Properties and Their Role in Hematopoiesis and Hematopoietic Stem Cell Transplantation

Stem Cell Reviews and Reports

Volumn 7, Issue 3, 2011, Pages 569-589

  Pontikoglou, Charalampos ^a,b,c   Deschaseaux, Frédéric ^b   Sensebé, Luc ^b   Papadaki, Helen A ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Bone marrow (BM); Graft versus host disease (GVHD); Hematopoiesis; Hematopoiestic stem cell transplantation (HSCT); Immunosuppression; Mesenchymal stem cells (MSCs); Myelodysplastic syndromes (MDS); Niche; Osteoblasts; Pericytes

Indexed keywords

ANIMAL; BONE MARROW CELL; CYTOLOGY; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEOSTASIS; HUMAN; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; PHYSIOLOGY; REVIEW;

ANIMALS; BONE MARROW CELLS; GRAFT VS HOST DISEASE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEOSTASIS; HUMANS; MESENCHYMAL STEM CELLS; MULTIPOTENT STEM CELLS;

EID: 79960290734     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-011-9228-8     Document Type: Review

References (210)

1. Schofield, R. (1978). The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells, 4(1-2), 7-25.
2. Friedenstein, A. J. (1990). Osteogenic stem cells in Bone Marrow. In J. N. M. Heersche & J. A. Kanis (Eds.), Bone and mineral research (pp. 243-272). Amsterdam: Elsevier.
3. Pittenger, M. F., Mackay, A. M., Beck, S. C., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284(5411), 143-147.
4. Bianco, P., Robey, P. G., & Simmons, P. J. (2008). Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell, 2(4), 313-319.
5. Caplan, A. I. (1991). Mesenchymal stem cells. Journal of Orthopaedic Research, 9(5), 641-650.
6. Horwitz, E. M., Le, B. K., Dominici, M., et al. (2005). Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy, 7(5), 393-395.
7. Kuznetsov, S. A., Friedenstein, A. J., & Robey, P. G. (1997). Factors required for bone marrow stromal fibroblast colony formation in vitro. British Journal Haematology, 97(3), 561-570.
8. Satomura, K., Krebsbach, P., Bianco, P., & Gehron, R. P. (2000). Osteogenic imprinting upstream of marrow stromal cell differentiation. Journal of Cellular Biochemistry, 78(3), 391-403.
9. Bianco, P., Robey, P. G., Saggio, I., & Riminucci, M. (2010). "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): a critical discussion of their nature, identity, and significance in incurable skeletal disease. Human Gene Therapy, 21(9), 1057-1066.
10. Sacchetti, B., Funari, A., Michienzi, S., et al. (2007). Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell, 131(2), 324-336.
11. Morikawa, S., Mabuchi, Y., Kubota, Y., et al. (2009). Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. The Journal of Experimental Medicine, 206(11), 2483-2496.
12. van Os, R., Kamminga, L. M., & de Haan, G. (2004). Stem cell assays: something old, something new, something borrowed. Stem Cells, 22(7), 1181-1190.
13. Dominici, M., Le, B. K., Mueller, I., et al. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8(4), 315-317.
14. Chamberlain, G., Fox, J., Ashton, B., & Middleton, J. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells, 25(11), 2739-2749.
15. Mosna, F., Sensebe, L., & Krampera, M. (2010). Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells and Development, 19(10), 1449-1470.
16. Galmiche, M. C., Koteliansky, V. E., Briere, J., Herve, P., & Charbord, P. (1993). Stromal cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular smooth muscle differentiation pathway. Blood, 82(1), 66-76.
17. Remy-Martin, J. P., Marandin, A., Challier, B., et al. (1999). Vascular smooth muscle differentiation of murine stroma: a sequential model. Experimental Hematology, 27(12), 1782-1795.
18. Delorme, B., Ringe, J., Pontikoglou, C., et al. (2009). Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells, 27(5), 1142-1151.
19. Wakitani, S., Saito, T., & Caplan, A. I. (1995). Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle & Nerve, 18(12), 1417-1426.
20. Makino, S., Fukuda, K., Miyoshi, S., et al. (1999). Cardiomyocytes can be generated from marrow stromal cells in vitro. Journal of Clinical Investigation, 103(5), 697-705.
21. Oswald, J., Boxberger, S., Jorgensen, B., et al. (2004). Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells, 22(3), 377-384.
22. Woodbury, D., Schwarz, E. J., Prockop, D. J., & Black, I. B. (2000). Adult rat and human bone marrow stromal cells differentiate into neurons. Journal of Neuroscience Research, 61(4), 364-370.
23. Chagraoui, J., Lepage-Noll, A., Anjo, A., Uzan, G., & Charbord, P. (2003). Fetal liver stroma consists of cells in epithelial-to-mesenchymal transition. Blood, 101(8), 2973-2982.
24. Charbord, P. (2010). Bone marrow mesenchymal stem cells: historical overview and concepts. Human Gene Therapy, 21(9), 1045-1056.
25. Delorme, B., Ringe, J., Gallay, N., et al. (2008). Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood, 111(5), 2631-2635.
26. Kastrinaki, M. C., Andreakou, I., Charbord, P., & Papadaki, H. A. (2008). Isolation of human bone marrow mesenchymal stem cells using different membrane markers: comparison of colony/cloning efficiency, differentiation potential, and molecular profile. Tissue Engineering Part C Methods, 14(4), 333-339.
27. da Silva, M. L., Caplan, A. I., & Nardi, N. B. (2008). In search of the in vivo identity of mesenchymal stem cells. Stem Cells, 26(9), 2287-2299.
28. Deschaseaux, F., Pontikoglou, C., & Sensebe, L. (2010). Bone regeneration: the stem/progenitor cells point of view. Journal of Cellular and Molecular Medicine, 14(1-2), 103-115.
29. Patel, S. A., Sherman, L., Munoz, J., & Rameshwar, P. (2008). Immunological properties of mesenchymal stem cells and clinical implications. Archivum Immunologiae et Therapiae Experimentalis (Warsz), 56(1), 1-8.
30. Bruder, S. P., Jaiswal, N., & Haynesworth, S. E. (1997). Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. Journal of Cellular Biochemistry, 64(2), 278-294.
31. Castro-Malaspina, H., Gay, R. E., Resnick, G., et al. (1980). Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood, 56(2), 289-301.
32. Pontikoglou, C., Delorme, B., & Charbord, P. (2008). Human bone marrow native mesenchymal stem cells. Regenerative Medicine, 3(5), 731-741.
33. Simmons, P. J., & Torok-Storb, B. (1991). Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood, 78(1), 55-62.
34. Martinez, C., Hofmann, T. J., Marino, R., Dominici, M., & Horwitz, E. M. (2007). Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood, 109(10), 4245-4248.
35. Gang, E. J., Bosnakovski, D., Figueiredo, C. A., Visser, J. W., & Perlingeiro, R. C. (2007). SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood, 109(4), 1743-1751.
36. Deschaseaux, F., & Charbord, P. (2000). Human marrow stromal precursors are alpha 1 integrin subunit-positive. Journal of Cellular Physiology, 184(3), 319-325.
37. Shi, S., & Gronthos, S. (2003). Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. Journal of Bone and Mineral Research, 18(4), 696-704.
38. Quirici, N., Soligo, D., Bossolasco, P., Servida, F., Lumini, C., & Deliliers, G. L. (2002). Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Experimental Hematology, 30(7), 783-791.
39. Takashima, Y., Era, T., Nakao, K., et al. (2007). Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell, 129(7), 1377-1388.
40. Morikawa, S., Mabuchi, Y., Niibe, K., et al. (2009). Development of mesenchymal stem cells partially originate from the neural crest. Biochemical and Biophysical Research Communications, 379(4), 1114-1119.
41. Crisan, M., Yap, S., Casteilla, L., et al. (2008). A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 3(3), 301-313.
42. da Silva, M. L., Chagastelles, P. C., & Nardi, N. B. (2006). Mesenchymal stem cells reside in virtually all post-natal organs and tissues. Journal of Cell Science, 119(Pt 11), 2204-2213.
43. Horwitz, E. M., Prockop, D. J., Fitzpatrick, L. A., et al. (1999). Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Natural Medicines, 5(3), 309-313.
44. Le, B. K., & Ringden, O. (2006). Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Current Opinion in Immunology, 18(5), 586-591.
45. Sensebe, L., Krampera, M., Schrezenmeier, H., Bourin, P., & Giordano, R. (2010). Mesenchymal stem cells for clinical application. Vox Sanguinis, 98(2), 93-107.
46. Prockop, D. J. (2009). Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Molecular Therapy, 17(6), 939-946.
47. da Silva Meirelles, L., Fontes, A. M., Covas, D. T., & Caplan, A. I. (2009). Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine & Growth Factor Reviews, 20(5-6), 419-427.
48. Uccelli, A., Moretta, L., & Pistoia, V. (2006). Immunoregulatory function of mesenchymal stem cells. European Journal of Immunology, 36(10), 2566-2573.
49. Le Blanc, K., & Ringden, O. (2007). Immunomodulation by mesenchymal stem cells and clinical experience. Journal of Internal Medicine, 262(5), 509-525.
50. Nauta, A. J., & Fibbe, W. E. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood, 110(10), 3499-3506.
51. Uccelli, A., Pistoia, V., & Moretta, L. (2007). Mesenchymal stem cells: a new strategy for immunosuppression? Trends in Immunology, 28(5), 219-226.
52. Uccelli, A., Moretta, L., & Pistoia, V. (2008). Mesenchymal stem cells in health and disease. Nature Reviews Immunology, 8(9), 726-736.
53. Bernardo, M. E., Locatelli, F., & Fibbe, W. E. (2009). Mesenchymal stromal cells. Annals of the New York Academy of Sciences, 1176, 101-117.
54. Siegel, G., Schafer, R., & Dazzi, F. (2009). The immunosuppressive properties of mesenchymal stem cells. Transplantation, 87(9 Suppl), S45-S49.
55. Eliopoulos, N., Stagg, J., Lejeune, L., Pommey, S., & Galipeau, J. (2005). Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood, 106(13), 4057-4065.
56. Nauta, A. J., Westerhuis, G., Kruisselbrink, A. B., Lurvink, E. G., Willemze, R., & Fibbe, W. E. (2006). Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood, 108(6), 2114-2120.
57. Tse, W. T., Pendleton, J. D., Beyer, W. M., Egalka, M. C., & Guinan, E. C. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation, 75(3), 389-397.
58. Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105(4), 1815-1822.
59. Krampera, M., Vitale, A., Vincenzi, C., et al. (2003). Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. British Journal Haematology, 120(1), 74-79.
60. Djouad, F., Plence, P., Bony, C., et al. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood, 102(10), 3837-3844.
61. Glennie, S., Soeiro, I., Dyson, P. J., Lam, E. W., & Dazzi, F. (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 105(7), 2821-2827.
62. Benvenuto, F., Ferrari, S., Gerdoni, E., et al. (2007). Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells, 25(7), 1753-1760.
63. Maccario, R., Podesta, M., Moretta, A., et al. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica, 90(4), 516-525.
64. Selmani, Z., Naji, A., Zidi, I., et al. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells. Stem Cells, 26(1), 212-222.
65. Opitz, C. A., Litzenburger, U. M., Lutz, C., et al. (2009). Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2, 3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells, 27(4), 909-919.
66. Liotta, F., Angeli, R., Cosmi, L., et al. (2008). Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells, 26(1), 279-289.
67. Augello, A., Tasso, R., Negrini, S. M., et al. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. European Journal of Immunology, 35(5), 1482-1490.
68. Corcione, A., Benvenuto, F., Ferretti, E., et al. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood, 107(1), 367-372.
69. Rasmusson, I., Le, B. K., Sundberg, B., & Ringden, O. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scandinavian Journal of Immunology, 65(4), 336-343.
70. Traggiai, E., Volpi, S., Schena, F., et al. (2008). Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells, 26(2), 562-569.
71. Jiang, W., Ma, A., Wang, T., et al. (2006). Intravenous transplantation of mesenchymal stem cells improves cardiac performance after acute myocardial ischemia in female rats. Transplant International, 19(7), 570-580.
72. Spaggiari, G. M., Abdelrazik, H., Becchetti, F., & Moretta, L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood, 113(26), 6576-6583.
73. Zhao, S., Wehner, R., Bornhauser, M., Wassmuth, R., Bachmann, M., & Schmitz, M. (2010). Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells and Development, 19(5), 607-614.
74. Kim, J., & Hematti, P. (2009). Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Experimental Hematology, 37(12), 1445-1453.
75. Raffaghello, L., Bianchi, G., Bertolotto, M., et al. (2008). Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells, 26(1), 151-162.
76. Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 24(1), 74-85.
77. Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C., & Moretta, L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107(4), 1484-1490.
78. Spaggiari, G. M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M. C., & Moretta, L. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood, 111(3), 1327-1333.
79. Stagg, J., Pommey, S., Eliopoulos, N., & Galipeau, J. (2006). Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood, 107(6), 2570-2577.
80. Chan, W. K., Lau, A. S., Li, J. C., Law, H. K., Lau, Y. L., & Chan, G. C. (2008). MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Experimental Hematology, 36(11), 1545-1555.
81. Francois, M., Romieu-Mourez, R., Stock-Martineau, S., Boivin, M. N., Bramson, J. L., & Galipeau, J. (2009). Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood, 114(13), 2632-2638.
82. Krebsbach, P. H., Kuznetsov, S. A., Bianco, P., & Robey, P. G. (1999). Bone marrow stromal cells: characterization and clinical application. Critical Reviews in Oral Biology and Medicine, 10(2), 165-181.
83. Dexter, T. M., Allen, T. D., & Lajtha, L. G. (1977). Conditions controlling the proliferation of haemopoietic stem cells in vitro. Journal of Cellular Physiology, 91(3), 335-344.
84. Dennis, J. E., Carbillet, J. P., Caplan, A. I., & Charbord, P. (2002). The STRO-1+ marrow cell population is multipotential. Cells, Tissues, Organs, 170(2-3), 73-82.
85. Charbord, P., Tavian, M., Humeau, L., & Peault, B. (1996). Early ontogeny of the human marrow from long bones: an immunohistochemical study of hematopoiesis and its microenvironment. Blood, 87(10), 4109-4119.
86. Westen, H., & Bainton, D. F. (1979). Association of alkaline-phosphatase-positive reticulum cells in bone marrow with granulocytic precursors. The Journal of Experimental Medicine, 150(4), 919-937.
87. Cattoretti, G., Schiro, R., Orazi, A., Soligo, D., & Colombo, M. P. (1993). Bone marrow stroma in humans: anti-nerve growth factor receptor antibodies selectively stain reticular cells in vivo and in vitro. Blood, 81(7), 1726-1738.
88. Omatsu, Y., Sugiyama, T., Kohara, H., et al. (2010). The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity, 33(3), 387-399.
89. Sugiyama, T., Kohara, H., Noda, M., & Nagasawa, T. (2006). Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity, 25(6), 977-988.
90. Wilson, A., & Trumpp, A. (2009). Hematopoietic stem cell niches. In A. Wickrema & B. Kee (Eds.), Molecular basis of hematopoiesis (pp. 47-71). New York: Springer.
91. Chan, C. K., Chen, C. C., Luppen, C. A., et al. (2009). Endochondral ossification is required for haematopoietic stem-cell niche formation. Nature, 457(7228), 490-494.
92. Kiel, M. J., Yilmaz, O. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., & Morrison, S. J. (2005). SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell, 121(7), 1109-1121.
93. Lo Celco, C., Fleming, H. E., Wu, J. W., et al. (2009). Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature, 457(7225), 92-96.
94. Xie, Y., Yin, T., Wiegraebe, W., et al. (2009). Detection of functional haematopoietic stem cell niche using real-time imaging. Nature, 457(7225), 97-101.
95. Mendez-Ferrer, S., Michurina, T. V., Ferraro, F., et al. (2010). Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature, 466(7308), 829-834.
96. Mendez-Ferrer, S., Chow, A., Merad, M., & Frenette, P. S. (2009). Circadian rhythms influence hematopoietic stem cells. Current Opinion in Hematology, 16(4), 235-242.
97. Koc, O. N., Gerson, S. L., Cooper, B. W., et al. (2000). Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. Journal of Clinical Oncology, 18(2), 307-316.
98. Devine, S. M., Bartholomew, A. M., Mahmud, N., et al. (2001). Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Experimental Hematology, 29(2), 244-255.
99. In 't Anker, P. S., Scherjon, S. A., Kleijburg-van der Keur, C., et al. (2003). Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood, 102(4), 1548-1549.
100. Bensidhoum, M., Chapel, A., Francois, S., et al. (2004). Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood, 103(9), 3313-3319.
101. Muguruma, Y., Yahata, T., Miyatake, H., et al. (2006). Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. Blood, 107(5), 1878-1887.
102. Gao, J., Dennis, J. E., Muzic, R. F., Lundberg, M., & Caplan, A. I. (2001). The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells, Tissues, Organs, 169(1), 12-20.
103. Barbash, I. M., Chouraqui, P., Baron, J., et al. (2003). Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation, 108(7), 863-868.
104. Lee, R. H., Pulin, A. A., Seo, M. J., et al. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5(1), 54-63.
105. Dazzi, F., Ramasamy, R., Glennie, S., Jones, S. P., & Roberts, I. (2006). The role of mesenchymal stem cells in haemopoiesis. Blood Reviews, 20(3), 161-171.
106. Majumdar, M. K., Thiede, M. A., Haynesworth, S. E., Bruder, S. P., & Gerson, S. L. (2000). Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. Journal of Hematotherapy & Stem Cell Research, 9(6), 841-848.
107. Di, N. M., Carlo-Stella, C., Magni, M., et al. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99(10), 3838-3843.
108. Prockop, D. J. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276(5309), 71-74.
109. Majumdar, M. K., Thiede, M. A., Mosca, J. D., Moorman, M., & Gerson, S. L. (1998). Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. Journal of Cellular Physiology, 176(1), 57-66.
110. Gottschling, S., Saffrich, R., Seckinger, A., et al. (2007). Human mesenchymal stromal cells regulate initial self-renewing divisions of hematopoietic progenitor cells by a beta1-integrin-dependent mechanism. Stem Cells, 25(3), 798-806.
111. Cheng, L., Qasba, P., Vanguri, P., & Thiede, M. A. (2000). Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells. Journal of Cellular Physiology, 184(1), 58-69.
112. Ichii, M., Oritani, K., Yokota, T., et al. (2008). Regulation of human B lymphopoiesis by the transforming growth factor-beta superfamily in a newly established coculture system using human mesenchymal stem cells as a supportive microenvironment. Experimental Hematology, 36(5), 587-597.
113. Morad, V., Pevsner-Fischer, M., Barnees, S., et al. (2008). The myelopoietic supportive capacity of mesenchymal stromal cells is uncoupled from multipotency and is influenced by lineage determination and interference with glycosylation. Stem Cells, 26(9), 2275-2286.
114. Lord, B. I., Testa, N. G., & Hendry, J. H. (1975). The relative spatial distributions of CFUs and CFUc in the normal mouse femur. Blood, 46(1), 65-72.
115. Gong, J. K. (1978). Endosteal marrow: a rich source of hematopoietic stem cells. Science, 199(4336), 1443-1445.
116. Askmyr, M., Sims, N. A., Martin, T. J., & Purton, L. E. (2009). What is the true nature of the osteoblastic hematopoietic stem cell niche? Trends in Endocrinology and Metabolism, 20(6), 303-309.
117. Taichman, R. S. (2005). Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood, 105(7), 2631-2639.
118. Taichman, R. S., & Emerson, S. G. (1998). The role of osteoblasts in the hematopoietic microenvironment. Stem Cells, 16(1), 7-15.
119. Zhu, J., Garrett, R., Jung, Y., et al. (2007). Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood, 109(9), 3706-3712.
120. Visnjic, D., Kalajzic, Z., Rowe, D. W., Katavic, V., Lorenzo, J., & Aguila, H. L. (2004). Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood, 103(9), 3258-3264.
121. Taichman, R. S., & Emerson, S. G. (1994). Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. The Journal of Experimental Medicine, 179(5), 1677-1682.
122. Calvi, L. M., Adams, G. B., Weibrecht, K. W., et al. (2003). Osteoblastic cells regulate the haematopoietic stem cell niche. Nature, 425(6960), 841-846.
123. Zhang, J., Niu, C., Ye, L., et al. (2003). Identification of the haematopoietic stem cell niche and control of the niche size. Nature, 425(6960), 836-841.
124. Kiel, M. J., & Morrison, S. J. (2008). Uncertainty in the niches that maintain haematopoietic stem cells. Nature Reviews Immunology, 8(4), 290-301.
125. Lymperi, S., Horwood, N., Marley, S., Gordon, M. Y., Cope, A. P., & Dazzi, F. (2008). Strontium can increase some osteoblasts without increasing hematopoietic stem cells. Blood, 111(3), 1173-1181.
126. Raaijmakers, M. H., Mukherjee, S., Guo, S., et al. (2010). Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature, 464(7290), 852-857.
127. Carlesso, N., & Cardoso, A. A. (2010). Stem cell regulatory niches and their role in normal and malignant hematopoiesis. Current Opinion in Hematology, 17(4), 281-286.
128. Oh, I. H., & Kwon, K. R. (2010). Concise review: multiple niches for hematopoietic stem cell regulations. Stem Cells, 28(7), 1243-1249.
129. Naveiras, O., Nardi, V., Wenzel, P. L., Hauschka, P. V., Fahey, F., & Daley, G. Q. (2009). Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature, 460(7252), 259-263.
130. Mufti, G. J. (2004). Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Practice & Research Clinical Haematology, 17(4), 543-557.
131. Greenberg, P. (2005). Pathogenetic mechanisms underlying myelodysplastic syndromes. In P. L. Greenberg (Ed.), Myelodysplastic syndromes: Clincal and biological advances (pp. 63-93). New York: Cambridge University Press.
132. Kastrinaki, M. C., Pontikoglou, C., Klaus, M., Stavroulaki, E., Pavlaki, K., Papadaki, H. A. (2010). Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes. Curr Stem Cell Res Ther.
133. Flores-Figueroa, E., Arana-Trejo, R. M., Gutierrez-Espindola, G., Perez-Cabrera, A., & Mayani, H. (2005). Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leukemia Research, 29(2), 215-224.
134. Klaus, M., Stavroulaki, E., Kastrinaki, M. C., et al. (2009). Reserves, functional, immunoregulatory and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells and Development, 19(7), 1043-1054.
135. Campioni, D., Moretti, S., Ferrari, L., Punturieri, M., Castoldi, G. L., & Lanza, F. (2006). Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. Haematologica, 91(3), 364-368.
136. Campioni, D., Rizzo, R., Stignani, M., et al. (2009). A decreased positivity for CD90 on human mesenchymal stromal cells (MSCs) is associated with a loss of immunosuppressive activity by MSCs. Cytometry Part B: Clinical Cytometry, 76(3), 225-230.
137. Lopez-Villar, O., Garcia, J. L., Sanchez-Guijo, F. M., et al. (2009). Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. Leukemia, 23(4), 664-672.
138. Flores-Figueroa, E., Montesinos, J. J., Flores-Guzman, P., et al. (2008). Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leukemia Research, 32(9), 1407-1416.
139. Zipori, D., Reichman, N., Arcavi, L., Shtalrid, M., Berrebi, A., & Resnitzky, P. (1985). In vitro functions of stromal cells from human and mouse bone marrow. Experimental Hematology, 13(7), 603-609.
140. Varga, G., Kiss, J., Varkonyi, J., et al. (2007). Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Pathology Oncology Research, 13(4), 311-319.
141. Kastrinaki, M. C., & Papadaki, H. A. (2009). Mesenchymal stromal cells in rheumatoid arthritis: biological properties and clinical applications. Current Stem Cell Research & Therapy, 4(1), 61-69.
142. Soenen-Cornu, V., Tourino, C., Bonnet, M. L., et al. (2005). Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. Oncogene, 24(15), 2441-2448.
143. Ramakrishnan, A., Awaya, N., Bryant, E., & Torok-Storb, B. (2006). The stromal component of the marrow microenvironment is not derived from the malignant clone in MDS. Blood, 108(2), 772-773.
144. Blau, O., Hofmann, W. K., Baldus, C. D., et al. (2007). Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Experimental Hematology, 35(2), 221-229.
145. Tarte, K., Gaillard, J., Lataillade, J. J., et al. (2010). Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. Blood, 115(8), 1549-1553.
146. Ozisik, Y. Y., Morgan, R., Peier, A., Meloni, A. M., & Sandberg, A. A. (1994). Trisomy 5 in long-term cultures from bone marrow of patients with solid tumors. Cancer Genetics and Cytogenetics, 78(2), 207-209.
147. Johansson, B., Heim, S., Mandahl, N., Mertens, F., & Mitelman, F. (1993). Trisomy 7 in nonneoplastic cells. Genes, Chromosomes & Cancer, 6(4), 199-205.
148. Broberg, K., Toksvig-Larsen, S., Lindstrand, A., & Mertens, F. (2001). Trisomy 7 accumulates with age in solid tumors and non-neoplastic synovia. Genes, Chromosomes & Cancer, 30(3), 310-315.
149. Kinne, R. W., Kunisch, E., Beensen, V., et al. (2003). Synovial fibroblasts and synovial macrophages from patients with rheumatoid arthritis and other inflammatory joint diseases show chromosomal aberrations. Genes, Chromosomes & Cancer, 38(1), 53-67.
150. Sloand, E. M., & Rezvani, K. (2008). The role of the immune system in myelodysplasia: implications for therapy. Seminars in Hematology, 45(1), 39-48.
151. Han, Q., Sun, Z., Liu, L., et al. (2007). Impairment in immuno-modulatory function of Flk1(+)CD31(-)CD34(-) MSCs from MDS-RA patients. Leukemia Research, 31(11), 1469-1478.
152. Zhi-Gang, Z., Wei-Ming, L., Zhi-Chao, C., Yong, Y., & Ping, Z. (2008). Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases. Leukaemia & Lymphoma, 49(11), 2187-2195.
153. Ferrara, J. L., Levine, J. E., Reddy, P., & Holler, E. (2009). Graft-versus-host disease. Lancet, 373(9674), 1550-1561.
154. Bacigalupo, A. (2007). Management of acute graft-versus-host disease. British Journal Haematology, 137(2), 87-98.
155. Chung, N. G., Jeong, D. C., Park, S. J., et al. (2004). Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. International Journal of Hematology, 80(4), 370-376.
156. Sudres, M., Norol, F., Trenado, A., et al. (2006). Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. Journal of Immunology, 176(12), 7761-7767.
157. Le Blanc, K., Rasmusson, I., Sundberg, B., et al. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 363(9419), 1439-1441.
158. Ringden, O., Uzunel, M., Rasmusson, I., et al. (2006). Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation, 81(10), 1390-1397.
159. Fang, B., Song, Y., Liao, L., Zhang, Y., & Zhao, R. C. (2007). Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplantation Proceedings, 39(10), 3358-3362.
160. Muller, I., Kordowich, S., Holzwarth, C., et al. (2008). Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells, Molecules & Diseases, 40(1), 25-32.
161. Le Blanc, K., Frassoni, F., Ball, L., et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371(9624), 1579-1586.
162. von Bonin, M., Stolzel, F., Goedecke, A., et al. (2009). Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplantation, 43(3), 245-251.
163. Lucchini, G., Introna, M., Dander, E., et al. (2010). PL-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft versus host disease in a pediatric population. Biology of Blood and Marrow Transplantation, 16(9), 1293-1301.
164. Kurtzerbrg, J., Prasad, V., Grimley, M., et al. (2010). Allogeneic human mesenchymal stem cell therapy (PROCHYMAL®) as a rescue agent for severe treatment resistant GVHD in pediatric patients. Biology of Blood and Marrow Transplantation, 16(2), S169.
165. Martin, P. J., Uberti, J. P., Soiffer, R. J., et al. (2010). Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a roandomizwd placebo-controlled, multicenter phase III trial in GVHD. Biology of Blood and Marrow Transplantation, 16(2), 169-170.
166. Kebriaei, P., Isola, L., Bahceci, E., et al. (2009). Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 15(7), 804-811.
167. Ning, H., Yang, F., Jiang, M., et al. (2008). The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia, 22(3), 593-599.
168. Almeida-Porada, G., Flake, A. W., Glimp, H. A., & Zanjani, E. D. (1999). Cotransplantation of stroma results in enhancement of engraftment and early expression of donor hematopoietic stem cells in utero. Experimental Hematology, 27(10), 1569-1575.
169. In 't Anker, P. S., Noort, W. A., Kruisselbrink, A. B., et al. (2003). Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Experimental Hematology, 31(10), 881-889.
170. Maitra, B., Szekely, E., Gjini, K., et al. (2004). Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplantation, 33(6), 597-604.
171. Angelopoulou, M., Novelli, E., Grove, J. E., et al. (2003). Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Experimental Hematology, 31(5), 413-420.
172. Lazarus, H. M., Haynesworth, S. E., Gerson, S. L., Rosenthal, N. S., & Caplan, A. I. (1995). Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplantation, 16(4), 557-564.
173. Lazarus, H. M., Koc, O. N., Devine, S. M., et al. (2005). Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology of Blood and Marrow Transplantation, 11(5), 389-398.
174. Le Blanc, K., Samuelsson, H., Gustafsson, B., et al. (2007). Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia, 21(8), 1733-1738.
175. Ball, L. M., Bernardo, M. E., Roelofs, H., et al. (2007). Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood, 110(7), 2764-2767.
176. Meuleman, N., Tondreau, T., Ahmad, I., et al. (2009). Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells and Development, 18(9), 1247-1252.
177. Karlsson, H., Samarasinghe, S., Ball, L. M., et al. (2008). Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood, 112(3), 532-541.
178. Baron, F., Lechanteur, C., Willems, E., et al. (2010). Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biology of Blood and Marrow Transplantation, 16(6), 838-847.
179. Macmillan, M. L., Blazar, B. R., DeFor, T. E., & Wagner, J. E. (2009). Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplantation, 43(6), 447-454.
180. Gonzalo-Daganzo, R., Regidor, C., Martin-Donaire, T., et al. (2009). Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults. Cytotherapy, 11(3), 278-288.
181. Bernardo, M. E., Ball, L. M., Cometa, A. M., et al. (2010). Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant.
182. Kushida, T., Inaba, M., Hisha, H., et al. (2001). Intra-bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood, 97(10), 3292-3299.
183. Poloni, A., Leoni, P., Buscemi, L., et al. (2006). Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia, 20(2), 329-335.
184. Krampera, M., Pizzolo, G., Aprili, G., & Franchini, M. (2006). Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone, 39(4), 678-683.
185. Jethva, R., Otsuru, S., Dominici, M., & Horwitz, E. M. (2009). Cell therapy for disorders of bone. Cytotherapy, 11(1), 3-17.
186. Mathiasen, A. B., Haack-Sorensen, M., & Kastrup, J. (2009). Mesenchymal stromal cells for cardiovascular repair: current status and future challenges. Future Cardiol, 5(6), 605-617.
187. Trivedi, P. S., Tray, N. J., Nguyen, T. D., Nigam, N., & Gallicano, G. I. (2010). Mesenchymal stem cell therapy for treatment of cardiovascular disease: helping people sooner or later. Stem Cells and Development, 19(7), 1109-1120.
188. Parr, A. M., Tator, C. H., & Keating, A. (2007). Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplantation, 40(7), 609-619.
189. Sadan, O., Melamed, E., & Offen, D. (2009). Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opinion on Biological Therapy, 9(12), 1487-1497.
190. Breitbach, M., Bostani, T., Roell, W., et al. (2007). Potential risks of bone marrow cell transplantation into infarcted hearts. Blood, 110(4), 1362-1369.
191. Miura, M., Miura, Y., Padilla-Nash, H. M., et al. (2006). Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells, 24(4), 1095-1103.
192. Zhou, Y. F., Bosch-Marce, M., Okuyama, H., et al. (2006). Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Cancer Research, 66(22), 10849-10854.
193. Aguilar, S., Nye, E., Chan, J., et al. (2007). Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells, 25(6), 1586-1594.
194. Li, H., Fan, X., Kovi, R. C., et al. (2007). Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: a model of age-related tumorigenesis in mice. Cancer Research, 67(22), 10889-10898.
195. Bernardo, M. E., Zaffaroni, N., Novara, F., et al. (2007). Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Research, 67(19), 9142-9149.
196. Rubio, D., Garcia-Castro, J., Martin, M. C., et al. (2005). Spontaneous human adult stem cell transformation. Cancer Research, 65(8), 3035-3039.
197. Rosland, G. V., Svendsen, A., Torsvik, A., et al. (2009). Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research, 69(13), 5331-5339.
198. Garcia, S., Bernad, A., Martin, M. C., Cigudosa, J. C., Garcia-Castro, J., & de la Fuente, R. (2010). Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Experimental Cell Research, 316(9), 1648-1650.
199. Torsvik, A., Rosland, G. V., Svendsen, A., et al. (2010). Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track-letter. Cancer Research, 70(15), 6393-6396.
200. Prockop, D. J., Brenner, M., Fibbe, W. E., et al. (2010). Defining the risks of mesenchymal stromal cell therapy. Cytotherapy, 12(5), 576-578.
201. Riggi, N., Cironi, L., Provero, P., et al. (2005). Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Research, 65(24), 11459-11468.
202. Tirode, F., Laud-Duval, K., Prieur, A., Delorme, B., Charbord, P., & Delattre, O. (2007). Mesenchymal stem cell features of Ewing tumors. Cancer Cell, 11(5), 421-429.
203. Riggi, N., Suva, M. L., Suva, D., et al. (2008). EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Research, 68(7), 2176-2185.
204. ]Riggi, N., Suva, M. L., De, V. C., et al. (2010). EWS-FLI-1modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes & Development, 24(9), 916-932.
205. Djouad, F., Bony, C., Apparailly, F., Louis-Plence, P., Jorgensen, C., & Noel, D. (2006). Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation, 82(8), 1060-1066.
206. Zhu, W., Xu, W., Jiang, R., et al. (2006). Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Experimental and Molecular Pathology, 80(3), 267-274.
207. Gunn, W. G., Conley, A., Deininger, L., Olson, S. D., Prockop, D. J., & Gregory, C. A. (2006). A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells, 24(4), 986-991.
208. Lazennec, G., & Jorgensen, C. (2008). Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells, 26(6), 1387-1394.
209. Orimo, A., Gupta, P. B., Sgroi, D. C., et al. (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 121(3), 335-348.
210. Mishra, P. J., Mishra, P. J., Humeniuk, R., et al. (2008). Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Research, 68(11), 4331-4339.